A multiscale mathematical model for oncolytic virotherapy

Cancer Research

Volumn 69, Issue 3, 2009, Pages 1205-1211

  Paiva, Leticia R ^a   Binny, Christopher ^b   Ferreira Jr , Silvio C ^a   Martins, Marcelo L ^a  

^a FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS;

ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CELL KILLING; COMPUTER SIMULATION; CYTOTOXICITY; IMMUNE RESPONSE; MATHEMATICAL MODEL; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SOLID TUMOR; STOCHASTIC MODEL; TUMOR CELL;

CELL GROWTH PROCESSES; MODELS, BIOLOGICAL; NEOPLASMS; ONCOLYTIC VIROTHERAPY;

EID: 59149087387     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2173     Document Type: Article

References (31)

1. Parato KA, Senger D, Forsyth PAJ, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-76.
2. Sebestyen Z, de Vrij J, Magnusson M, Debets R, Willemsen R. An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. Cancer Res 2007;67:11309-16.
3. Kawashima T, Kagawa S, Kobayashi N, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004;10:285-92.
4. Yu D-C, Chen Y, Seng M, Dilley J, Henderson DR. The Addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999;59:4200-3.
5. Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish I A. Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene 2008;27:3081-90.
6. Liu T-C, Galanis E, Kim D. Clinical trials results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Prac Onc 2007;4:101-17.
7. Ferreira SC, Jr., Martins ML, Vilela MJ. Fighting cancer with viruses. Phys A 2005;345:591-602.
8. Martins ML, Ferreira SC, Jr., Vilela MJ. Multiscale models for the growth of avascular tumors. Phys Life Rev 2007;4:128-56.
9. Ferreira SC, Jr., Martins ML, Vilela MJ. Reaction-diffusion model for the growth of avascular tumors. Phys Rev E 2002;65:021907.
10. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg 1998;228:366-74.
11. Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res 2001;61:3501-7.
12. Wein LM, Wu JT, Kirn DH. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 2003;63:1317-24.
13. Weinberg R. The biology of cancer. New York: Garland Science; 2007.
14. Ferreira SC, Jr., Martins ML, Vilela MJ. Morphology transitions induced by chemoterapy in carcinomas in situ. Phys Rev E 2003;67:051914.
15. Wu JT, Kirn DH, Wein LM. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bull Math Biol 2004;66:605-25.
16. Coffey MC, Strong JE, Forsyth PA, Lee PWK. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-4.
17. White CL, Twigger KR, Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008;15:911-20.
18. Wang Y, Hallden G, Hill R, et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 2003;21:1328-35.
19. Hu W, Davis JJ, Zhu H, et al. Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy. Cancer Biol Ther 2007;6:1773-9.
20. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 2002;76:895-904.
21. Foloppe J, Kintz J, Futin N, et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008;15:1361-71.
22. Cheng J, Sauthoff H, Huang YQ, et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther 2007;15:1982-90.
23. Morris DG, Forsyth P, Roldan G, et al. A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies [abstract92]. Proc Am Soc Clin Oncol 2002;21:a24.
24. Nemunaitis J, Ganly I, Khury F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55 kd gene-delected adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000;60:6359-66.
25. Ganly I, Kirn D, Eckhardt SG, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000;6:798-806.
26. Nemunaitis J, Khury F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-98.
27. Peng KW, Hadac EM, Anderson BD, et al. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther 2006;13:732-8.
28. Milton GW, Brown MM. The limited role of attenuated smallpox virus in the management of advanced malignant melanoma. Aust N Z J Surg 1966;35:286-90.
29. Mastrangelo MJ, Maguire HC, Jr., Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melenoma. Cancer Gene Ther 1999;6:409-22.
30. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003;9:123-8.
31. Nagano S, Perentes JY, Jain RK, Boucher Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res 2008;68:3795-802.